{"id":67416,"date":"2026-06-05T13:44:55","date_gmt":"2026-06-05T05:44:55","guid":{"rendered":"https:\/\/flcube.com\/?p=67416"},"modified":"2026-06-05T13:44:56","modified_gmt":"2026-06-05T05:44:56","slug":"teva-launches-ahzantive-biosimilar-to-bayers-eylea-across-europe-expanding-access-to-retinal-disease-treatments","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67416","title":{"rendered":"Teva Launches Ahzantive Biosimilar to Bayer&#8217;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Teva Pharmaceutical Industries Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TEVA:NYSE\">NYSE: TEVA<\/a>) announced the commercial launch of <strong>Ahzantive<\/strong>, its <strong>biosimilar version<\/strong> of <strong>Bayer AG&#8217;s<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) <strong>Eylea (aflibercept)<\/strong>, across multiple European markets.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-commercial-milestone\" class=\"wp-block-heading\">Regulatory &amp; Commercial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Ahzantive (aflibercept biosimilar)<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Bayer&#8217;s Eylea (aflibercept)<\/td><\/tr><tr><td><strong>Launch Markets<\/strong><\/td><td>France, Germany, Spain, Netherlands (May 2026)<\/td><\/tr><tr><td><strong>Additional Markets<\/strong><\/td><td>Planned launches later in 2026<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Neovascular (wet) age-related macular degeneration (AMD)<br>Macular edema secondary to retinal vein occlusion (RVO)<br>Diabetic macular edema (DME)<br>Myopic choroidal neovascularization (mCNV)<\/td><\/tr><tr><td><strong>Dosage Form<\/strong><\/td><td>Prefilled syringe<\/td><\/tr><tr><td><strong>Commercial Partners<\/strong><\/td><td>Klinge Biopharma GmbH and Formycon AG (semi-exclusive agreements)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-therapeutic-impact\" class=\"wp-block-heading\">Market Opportunity &amp; Therapeutic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Access:<\/strong> Provides patients with serious retinal diseases greater access to cost-effective biosimilar treatment options<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> European retinal disease market valued at \u20ac4.2 billion annually, with Eylea commanding significant market share<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Biosimilars typically priced 15-30% below reference products, creating substantial healthcare savings<\/li>\n\n\n\n<li><strong>Treatment Burden:<\/strong> Addresses high unmet need in chronic retinal conditions requiring frequent intravitreal injections<\/li>\n\n\n\n<li><strong>Healthcare Systems:<\/strong> Expected to generate \u20ac300-500 million in annual savings for European healthcare systems by 2028<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Structure<\/strong><\/td><td>Semi-exclusive commercialization agreements<\/td><\/tr><tr><td><strong>Geographic Coverage<\/strong><\/td><td>Most of Europe plus Israel<\/td><\/tr><tr><td><strong>Partners<\/strong><\/td><td><strong>Klinge Biopharma GmbH<\/strong> and <strong>Formycon AG<\/strong><\/td><\/tr><tr><td><strong>Teva&#8217;s Role<\/strong><\/td><td>Commercial distribution and market access<\/td><\/tr><tr><td><strong>Partner Contributions<\/strong><\/td><td>Development expertise and regulatory support<\/td><\/tr><tr><td><strong>Revenue Sharing<\/strong><\/td><td>Terms undisclosed, typical biosimilar partnerships involve tiered royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Position<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Bayer&#8217;s Eylea<\/strong><\/td><td>Market leader with \u20ac5.8 billion global sales in 2025; faces increasing biosimilar competition<\/td><\/tr><tr><td><strong>Existing Biosimilars<\/strong><\/td><td>Limited competition in European market; Ahzantive represents second major entrant<\/td><\/tr><tr><td><strong>Teva&#8217;s Strategy<\/strong><\/td><td>Leverages extensive European commercial infrastructure and ophthalmology expertise<\/td><\/tr><tr><td><strong>Pricing Pressure<\/strong><\/td><td>Expected to accelerate price erosion for reference product across all indications<\/td><\/tr><tr><td><strong>Market Share Projection<\/strong><\/td><td>Teva targeting 15-20% biosimilar market share within 24 months of full European rollout<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-financial-implications\" class=\"wp-block-heading\">Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Contribution:<\/strong> Modest but steady revenue stream expected, with peak annual sales projected at $200-300 million globally<\/li>\n\n\n\n<li><strong>Margin Profile:<\/strong> High-margin specialty pharmaceutical product supporting Teva&#8217;s strategic shift toward complex generics and biosimilars<\/li>\n\n\n\n<li><strong>Investment Return:<\/strong> Low-risk commercial opportunity leveraging existing infrastructure with minimal additional capital expenditure required<\/li>\n\n\n\n<li><strong>Strategic Alignment:<\/strong> Supports Teva&#8217;s broader portfolio diversification away from traditional generics toward higher-value specialty products<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding product launches, market opportunities, and financial projections for Ahzantive. Actual results may differ due to risks including competitive dynamics, pricing pressures, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67417,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,967,40,1072,44,1071],"class_list":["post-67416","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-market-launch","tag-nyse-teva","tag-ophthalmology","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Teva Launches Ahzantive Biosimilar to Bayer&#039;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version of Bayer AG&#039;s (ETR: BAYN) Eylea (aflibercept), across multiple European markets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67416\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teva Launches Ahzantive Biosimilar to Bayer&#039;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments\" \/>\n<meta property=\"og:description\" content=\"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version of Bayer AG&#039;s (ETR: BAYN) Eylea (aflibercept), across multiple European markets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67416\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:44:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:44:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Teva Launches Ahzantive Biosimilar to Bayer&#8217;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments\",\"datePublished\":\"2026-06-05T05:44:55+00:00\",\"dateModified\":\"2026-06-05T05:44:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0502.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Market launch\",\"NYSE: TEVA\",\"Ophthalmology\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67416#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67416\",\"name\":\"Teva Launches Ahzantive Biosimilar to Bayer's Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0502.webp\",\"datePublished\":\"2026-06-05T05:44:55+00:00\",\"dateModified\":\"2026-06-05T05:44:56+00:00\",\"description\":\"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version of Bayer AG's (ETR: BAYN) Eylea (aflibercept), across multiple European markets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67416\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Teva Launches Ahzantive Biosimilar to Bayer's Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67416#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Teva Launches Ahzantive Biosimilar to Bayer&#8217;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teva Launches Ahzantive Biosimilar to Bayer's Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments - Insight, China&#039;s Pharmaceutical Industry","description":"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version of Bayer AG's (ETR: BAYN) Eylea (aflibercept), across multiple European markets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67416","og_locale":"en_US","og_type":"article","og_title":"Teva Launches Ahzantive Biosimilar to Bayer's Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments","og_description":"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version of Bayer AG's (ETR: BAYN) Eylea (aflibercept), across multiple European markets.","og_url":"https:\/\/flcube.com\/?p=67416","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:44:55+00:00","article_modified_time":"2026-06-05T05:44:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67416#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67416"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Teva Launches Ahzantive Biosimilar to Bayer&#8217;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments","datePublished":"2026-06-05T05:44:55+00:00","dateModified":"2026-06-05T05:44:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67416"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67416#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp","keywords":["Bayer","ETR: BAYN","Market launch","NYSE: TEVA","Ophthalmology","Teva Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67416#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67416","url":"https:\/\/flcube.com\/?p=67416","name":"Teva Launches Ahzantive Biosimilar to Bayer's Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67416#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67416#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp","datePublished":"2026-06-05T05:44:55+00:00","dateModified":"2026-06-05T05:44:56+00:00","description":"Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version of Bayer AG's (ETR: BAYN) Eylea (aflibercept), across multiple European markets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67416#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67416"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67416#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp","width":1080,"height":608,"caption":"Teva Launches Ahzantive Biosimilar to Bayer's Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67416#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Teva Launches Ahzantive Biosimilar to Bayer&#8217;s Eylea Across Europe \u2013 Expanding Access to Retinal Disease Treatments"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67416"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67416\/revisions"}],"predecessor-version":[{"id":67418,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67416\/revisions\/67418"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67417"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}